Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HURA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTuHURA files updated pro forma financials for Kineta acquisition, approves executive raises
Filed April 8, 2026 · Period ending April 2, 2026 · ~1 min read
Key Changes
-
medium
Company provides updated pro forma financials showing combined TuHURA-Kineta operations for full year 2025, as if the June 2025 acquisition had closed January 1. Gives clearer picture of merged entity's performance.
Item 9.01 verify on EDGAR → -
low
CEO Dr. James Bianco received $490,536 bonus for 2025 performance and 5% salary increase to $605,956 annually, effective April 2, 2026.
Item 5.02 verify on EDGAR → -
low
CFO Dan Dearborn received $163,393 bonus for 2025 performance and 5% salary increase to $403,676 annually, effective April 2, 2026.
Item 5.02 verify on EDGAR →
Summary
TuHURA Biosciences filed updated pro forma financial statements showing what the combined company's 2025 results would have looked like if its acquisition of Kineta, Inc. had closed on January 1, 2025, rather than the actual June 30, 2025 closing date.
This supplemental disclosure helps investors understand the full-year economics of the merged entity, which is particularly relevant for a biotech company where R&D spending and cash burn rates are critical metrics. Separately, the Compensation Committee approved routine year-end compensation adjustments for the CEO and CFO. Dr.
Bianco received a $490,536 bonus for 2025 performance plus a 5% cost-of-living salary increase, while CFO Dearborn received a $163,393 bonus and matching 5% raise. These are standard executive compensation actions with minimal impact on shareholder value.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
TuHURA approved 2025 bonuses and 5% salary increases for CEO and CFO effective April 2, 2026.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) approved annual performance bonuses for 2025 for Dr. James Bianco, the Company’s President and Chief Executive Officer, and Dan Dearborn, the Company’s Chief Financial Officer, in the amount of $490,536 for Dr. Bianco
The Compensation Committee approved a 2025 annual performance bonus of $490,536 for CEO Dr. James Bianco. This represents compensation for the prior fiscal year's performance.
Added in current filing · verify on EDGAR →
approved annual performance bonuses for 2025 for Dr. James Bianco, the Company’s President and Chief Executive Officer, and Dan Dearborn, the Company’s Chief Financial Officer, in the amount of $490,536 for Dr. Bianco and $163,393 for Mr. Dearborn
The Compensation Committee approved a 2025 annual performance bonus of $163,393 for CFO Dan Dearborn. This represents compensation for the prior fiscal year's performance.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
on June 30, 2025, the Company completed its previously announced acquisition contemplated by the Agreement and Plan of Merger, dated December 11, 2024, as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025
The filing confirms the Kineta acquisition closed on June 30, 2025, under a merger agreement originally signed December 11, 2024 and amended May 5, 2025. The transaction involved a two-step merger structure where Kineta merged into a TuHURA subsidiary, which then merged into another subsidiary.
Event · Item 9.01 — Financial Statements and Exhibits
TuHURA filed unaudited pro forma financial statements for year ended December 31, 2025, a routine procedural disclosure.
Added in current filing · verify on EDGAR →
The following unaudited pro forma financial information of the Company is attached as Exhibit 99.1 to this Report and incorporated by reference herein:
•
Unaudited Pro Forma Condensed Combined Statement of Operations for the Company for the year ended December 31, 2025.
The company filed unaudited pro forma condensed combined statement of operations for the year ended December 31, 2025. Pro forma financials typically reflect adjustments for significant transactions like acquisitions or restructurings to show what historical results would have looked like under current structure. The actual exhibit content is not included in this 8-K body, only referenced.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify